Alzheimer, Insurance Companies, and Health: A Growing Global Concern

Web Editor

October 28, 2025

a woman in a black jacket and white shirt is standing in front of a blue background with a yellow bo

Understanding Alzheimer’s Disease

For many years, Alzheimer’s disease, originating from a German name, was shrouded in mystery with little public knowledge. This progressive neurodegenerative disease, however, poses a significant global health challenge.

In 2019, the socioeconomic global cost of dementia was estimated at $1.31 trillion, projected to reach $2.8 trillion by 2030. Currently, over 55 million people worldwide live with dementia, with Alzheimer’s being the primary cause. Alarmingly, approximately 10 million new cases are reported annually.

The Mexican Scenario

In Mexico, it is estimated that 1.3 million individuals suffer from Alzheimer’s, a figure expected to triple by 2050. Medical studies and global research highlight that only 17% of Alzheimer’s cases are diagnosed promptly.

Advancements in Diagnosis and Treatment

Historically, distinguishing Alzheimer’s from other dementias was not a priority due to the lack of specific treatments. Today, advancements in biomarkers and neuroimaging enable detection 15-20 years before clinical symptoms, allowing for timely intervention during mild cognitive impairment stages.

The Role of Insurance Companies

Given the health priority for any nation and its potential impact on families, addressing Alzheimer’s is crucial. Financially, families often struggle to cope with this disease. Consequently, it’s vital for insurance companies to seriously consider including Alzheimer’s coverage in their medical policies.

Private insurance companies in Mexico have started recognizing Alzheimer’s as a neurodegenerative disease, covering medication. This shift signifies a more inclusive and equitable coverage.

Lilly’s Contribution

Pharmaceutical company Lilly has been at the forefront of Alzheimer’s research in Mexico for three decades. Their advanced monoclonal antibody, Donanemab, was developed over a decade with billions of dollars in investment.

Lilly projects that by 2030, Alzheimer’s will be treated as a chronic condition. However, it is equally important for the national health sector to prioritize prevention in this area.

Water Supply Irregularities at Time Ceramic

Irrelevant Attitude Towards Water Supply Issues

Despite ongoing irregularities in water supply affecting Time Ceramic, the company seems unconcerned. This firm is expanding its investments into sports, specifically supporting the Tuzos team. The pressing question is whether Time Ceramic’s legal challenges in Hidalgo are overlooked or if more severe consequences are needed to address the water supply issues seriously.